Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Gastrointestinal 4CNS 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 134pembrolizumab 113Pemetrexed 94Cisplatin 88durvalumab 62Paclitaxel 60osimertinib 54Nivolumab 54Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × tucatinib × Thoracic × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡